Trial Profile
A 52-Week,Multi-Center,Randomized,Double-Blind,Placebo-Controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Aug 2019
Price :
$35
*
At a glance
- Drugs Amilomotide (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- Sponsors Novartis
- 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.
- 11 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov [parent trial: NCT00733863].
- 10 Jul 2010 Immunogenicity results presented at the 2010 International Conference on Alzheimer's Disease and Related Disorders.